Search Results - "Gursoz, Hakki"

Assessment of quarter billion primary care prescriptions from a nationwide antimicrobial stewardship program by Gönen, Mehmet, Aksoy, Mesil, İşli, Fatma, Gürpınar, Umut Emre, Göbel, Pınar, Gürsöz, Hakkı, Ergönül, Önder

“…We described the significance of systematic monitoring nationwide antimicrobial stewardship programs (ASPs) in primary care. All the prescriptions given by…”
Get full text

Evaluation of the Performance of the Turkish Regulatory Agency: Recommendations for Improved Patients' Access to Medicines by Koyuncu, Oguzhan, Gursoz, Hakki, Alkan, Ali, Cetintas, Hacer Coskun, Pasaoglu, Tuncay, Mashaki Ceyhan, Emel, Walker, Stuart

“…This study was to evaluate the Turkish regulatory review process and timelines between 2016 and 2018 with a view to assess the changes that had taken place…”
Get full text

Assessment of the Turkish health care system reforms: A stakeholder analysis by Akinci, Fevzi, Mollahaliloğlu, Salih, Gürsöz, Hakki, Öğücü, Fatma

“…Abstract Background The Turkish health care system has been undergoing a significant transformation with the Health Transformation Program (HTP) since 2003…”
Get full text

The Turkish Medicines and Medical Devices Agency: Comparison of Its Registration Process with Australia, Canada, Saudi Arabia, and Singapore by Mashaki Ceyhan, Emel, Gürsöz, Hakki, Alkan, Ali, Coşkun, Hacer, Koyuncu, Oğuzhan, Walker, Stuart

“…Regulatory agency comparisons can be of more value and facilitate improvements if conducted among countries with common challenges and similar health agency…”
Get full text

Evaluation of off‐label anti‐vascular endothelial growth factor and steroid implant medication uses in macular edema due to retinal vein occlusion in Turkey by Yilmaz, Mevlut, Citirik, Mehmet, Rahmanlar, Hanife, Alkan, Ali, Gursoz, Hakki

“…What is Known and Objective Retinal vein occlusion (RVO) is one of the most common causes of vision loss. Anti‐vascular endothelial growth factor (anti‐VEGF)…”
Get full text

Off-Label uses of ranibizumab and aflibercept for age-related macular degeneration in Turkey by Yilmaz, Mevlut, Citirik, Mehmet, Rahmanlar, Hanife, Alkan, Ali, Gursoz, Hakki

“…Purpose: To evaluate the clinical and demographic aspects of off-label drug use applications for age-related macular degeneration (AMD) in Turkey. Methods:…”
Get full text

Evaluation of more than one billion outpatient prescriptions and eight‐year trend showing a remarkable reduction in antibiotic prescription in Turkey: A success model of governmental interventions at national level by Aksoy, Mesil, Isli, Fatma, Kadi, Esma, Varimli, Didem, Gursoz, Hakki, Tolunay, Tolga, Kara, Ates, Unal, Serhat, Alp Mese, Emine

“…Purpose To present the antibiotic prescription trend between 2011–2018 at primary healthcare in Turkey in order to evaluate the effects of interventions at…”
Get full text

Off-label uses of Aflibercept, Ranibizumab and Dexamethasone implant for diabetic retinopathy in Turkey by Yilmaz, Mevlut, Citirik, Mehmet, Rahmanlar, Hanife, Alkan, Ali, Gursoz, Hakki

“…Diabetic retinopathy (DRP) is the most common retinal vascular disease leading to blindness. There is limited data about the off-label drug use for DRP and…”
Get full text

Relative risk of tuberculosis in patients with rheumatic diseases managed with anti‐tumour necrosis factor‐alpha therapy: A nationwide cohort study by Aydin, Volkan, Akici, Ahmet, Isli, Fatma, Aksoy, Mesil, Aydin, Mehtap, Gursoz, Hakki

“…Summary What is known and objective Anti‐tumour necrosis factor‐alpha (anti‐TNF‐α) therapy is known to raise the risk of granulomatous infections, leading to…”
Get full text

Biological therapy for ocular Behçet’s disease with off-label drug prescription in Turkey by Citirik, Mehmet, Ucgul Atilgan, Cemile, Rahmanlar, Hanife, Alkan, Ali, Gursoz, Hakki

“…ObjectiveThe use of biological agents in the treatment of ocular Behçet’s disease has recently become more frequent. The use of two agents, infliximab (IFX)…”
Get full text

A Multifaceted Evaluation of National Off-label Neurology Applications/Ulusal Endikasyon Disi Noroloji Basvurularinin Cok Yonlu Degerlendirilmesi by Yurtogullari, Sukran, Rahmanlar, Hanife, Alkan, Ali, Bayar, Banu, Gursoz, Hakki, Adatepe, Nurten Uzun

“…Objective: Off-label drug use (OLDU) of neurologic diseases is approved by a regulatory authority, the Turkish Medicines and Medical Devices Agency (TMMDA) in…”
Get full text

Systemic antimycotic and antifungal use in eastern Europe: a cross-national database study in coordination with the WHO Regional Office for Europe by Adriaenssens, Niels, Uka, Valdet, Versporten, Ann, Bolokhovets, Ganna, Ghazaryan, Lilit, Abilova, Vafa, Pyshnik, Galina, Spasojevic, Tijana, Korinteli, Irma, Kambaralieva, Baktygul, Cizmovic, Lidija, Carp, Angela, Radonjic, Vesela, Maqsudova, Nargis, Alkan, Ali, Coenen, Samuel, Pedersen, Hanne Bak, Sautenkova, Nina, Goossens, Herman

Get full text

A Multifaceted Evaluation of National Off-label Neurology Applications by Yurtoğulları, Şükran, Rahmanlar, Hanife, Alkan, Ali, Bayar, Banu, Gürsöz, Hakkı, Uzun Adatepe, Nurten

“…Objective: Off-label drug use (OLDU) of neurologic diseases is approved by a regulatory authority, the Turkish Medicines and Medical Devices Agency (TMMDA) in…”
Get full text

Results of reference pricing and reimbursement discount rate schemes of Turkey by Guvenc Kockaya, Kagan Atikeler, Esin Tuna, Pelin Kılıc, Pelin Tanyeri, Nurcan Umman, İsmail Mert Vural, Omer Altun, Akif Akbulat, Guven Artiran, Ercan Simsek, Hakkı Gursoz, Saim Kerman

“…OBJECTIVES: General Directorate of Pharmaceuticals and Pharmacy (IEGM) is responsible for setting all prices for human medicinal products. The reference…”
Get full text

Treatment cost of metastatic colon cancer in Turkey by Guvenc Kockaya, Mine Polat, Albert Wertheimer, Ahmet Ozet, Simten Malhan, İsmail Mert Vural, Akif Akbulat, Guven Artıran, Hakkı Gursoz, Saim Kerman

“…OBJECTIVES: Colon cancer is the third most common in the top cancer incidence list in Europe. In Europe 212,000 patients die every year due to colon cancer. In…”
Get full text

ADHD Medication Trends in Turkey: 2009-2013 by Öner, Özgür, Yilmaz, Esra Şafak, Karadağ, Hasan, Vural, Mert, Vural, Elif Hilal, Akbulat, Akif, Gürsöz, Hakkı, Türkçapar, Hakan, Kerman, Saim

“…Objective: To investigate the change of ADHD medication prescriptions in Turkey between 2009 and 2013. Method: Consumption data of ADHD medications, immediate…”
Get full text

Evaluation of Top-selling Biotechnological Medicine from 2003 to 2016 in Turkey by Vural, Elif Hilal, Şafak Yılmaz, Esra, Bektemür, Güven, Vural, İsmail Mert, Bayar, Banu, Gürsöz, Hakkı

“…Aim: The top 100 medicines having the highest annual average sales between the years 2006 and 2015, had exceeded one-fourth of the total pharmaceutical…”
Get full text

A nationwide evaluation of off-label drug utilization in Turkey by Özdamar, Emine Nur, Akıcı, Ahmet, Alkan, Ali, Bayar, Banu, Gürsöz, Hakkı

“…Background/aim: Off-label drug use (OLDU) is under the control of the Turkish Medicines and Medical Devices Agency (TMMDA) in Turkey. It was aimed to…”
Get full text

Türkiye’de Diyabetik Retinopati Tanısında Endikasyon Dışı İlaç Kullanımı by Rahmanlar, Hanife, Üçgül Atılgan, Cemile, Çıtırık, Mehmet, Yaradılmış, İbrahim Muaz, Gürsöz, Hakkı

“…Amaç: Türkiye’de diyabetik retinopatisi olan hastalarda endikasyon dışı ilaç kullanımı için yapılan başvuruların demografik özelliklerini değerlendirmek. Gereç…”
Get full text

Türkiye’de Yaşa Bağlı Maküla Dejenerasyonunda Endikasyon Dışı İlaç Kullanımı by RAHMANLAR, Hanife, ÜÇGÜL ATILGAN, Cemile, ÇITIRIK, Mehmet, ALKAN, Ali, GÜRSÖZ, Hakkı

“…Amaç: Türkiye’de yaşa bağlı maküla dejenerasyonu (YBMD) olan hastalarda endikasyon dışı (off-label) ilaç kullanımı için yapılan başvuruların demografik…”
Get full text